

ASX Announcement

Results of Annual General Meeting

27 November 2023 – Race Oncology Limited (“Race”) advises that its Annual General Meeting of Shareholders was held today at 12.00 pm AEDT.

The resolutions were voted in accordance with the Notice of Annual General Meeting previously advised to the Australian Securities Exchange.

All resolutions were passed on a poll.

Further information required by section 251AA(2) of the Corporations Act 2001 (Cth) is attached to this announcement.

-ENDS-

About Race Oncology (ASX: RAC)

Race Oncology (ASX: RAC) is an ASX-listed clinical stage biopharmaceutical company with a dedicated mission to be at the heart of cancer care.

Race’s lead asset, bisantrene, is a small molecule chemotherapeutic. Bisantrene has a rich and unique clinical history with demonstrated therapeutic benefits in both adult and paediatric patients, a well characterised safety profile, and compelling clinical data demonstrating an anticancer effect and less cardiotoxicity over certain anthracyclines, such as doxorubicin.

Race is advancing a reformulated bisantrene (RC220) to address the high unmet needs of patients across multiple oncology indications, with a clinical focus on anthracycline combinations, where we hope to deliver cardioprotection and enhanced anti-cancer activity in solid tumours. Race is also exploring RC220 as a low intensity treatment for acute myeloid leukaemia.

Race is investigating the effect of bisantrene on the m6A RNA pathway, following independent research published by the City of Hope identifying bisantrene as a potent inhibitor of FTO (Fat mass and obesity-associated protein). Dysregulation of the m6A RNA pathway has been described in numerous peer reviewed studies to be a driver of a diverse range of cancers.

Race Oncology has collaborated with Astex, City of Hope, MD Anderson, Sheba City of Health, UNC School of Medicine, University of Wollongong and University of Newcastle, and is actively exploring partnerships, licence agreements or a commercial merger and acquisition to accelerate access to bisantrene for patients with cancer across the world.

Learn more at www.raceoncology.com.

If you have any questions on this announcement or any past Race Oncology announcements, please go to the Interactive Announcements page in our Investor Hub <https://announcements.raceoncology.com>

Race encourages all investors to go paperless by registering their details with the Company’s share registry, Automic Registry Services, at www.automicgroup.com.au.

Release authorised by:

The Race Oncology Board of Directors
info@raceoncology.com

Media contact:

Jane Lowe +61 411 117 774
jane.lowe@irdepartment.com.au

Disclosure of Proxy Votes

Race Oncology Limited

Annual General Meeting

Monday, 27 November 2023



Automic

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E hello@automic.com.au

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	Proxy Votes				Poll Results (if applicable)			Results
			FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
1 ADOPTION OF REMUNERATION REPORT	P	28,847,882	24,100,836 83.54%	2,036,295 7.06%	366,210	2,710,751 9.40%	30,573,220 93.42%	2,154,295 6.58%	366,210	-
2 ELECTION OF DIRECTOR – DR PETER SMITH	P	45,951,409	43,233,152 94.08%	107,506 0.23%	14,127	2,610,751 5.68%	49,746,936 99.78%	107,506 0.22%	14,127	Passed
3 RE-ELECTION OF DIRECTOR – PHILLIP LYNCH	P	45,507,260	41,097,860 90.31%	1,800,434 3.96%	458,276	2,608,966 5.73%	46,706,790 94.53%	2,703,503 5.47%	458,276	Passed
4 ISSUE OF DIRECTOR OPTIONS TO DIRECTOR – MARY HARNEY	P	28,871,900	23,234,858 80.48%	2,913,112 10.09%	342,192	2,723,930 9.43%	28,836,193 88.62%	3,702,465 11.38%	555,067	Passed
5 ISSUE OF DIRECTOR OPTIONS TO DIRECTOR – PETER SMITH	P	29,136,850	25,696,461 88.19%	829,459 2.85%	77,242	2,610,930 8.96%	32,067,024 97.12%	949,459 2.88%	77,242	Passed

